Lista de obras - Lucia Nappi - Dominio Público Uruguay

Addition of erlotinib to fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab: Two sequential phase I trials

artículo científico publicado en 2011

Avelumab and axitinib combination therapy for the treatment of advanced renal cell carcinoma

artículo científico publicado en 2020

Building the Case for Adjuvant Chemotherapy After Radical Cystectomy: Commentary on: Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer

artículo científico publicado en 2016

Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis.

artículo científico publicado en 2017

Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis.

artículo científico publicado en 2016

Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma.

artículo científico publicado en 2013

Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models

artículo científico publicado en 2014

Hsp27 Inhibition with OGX-427 Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy.

artículo científico publicado en 2015

Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to antiepidermal growth factor receptor antibody.

artículo científico publicado en 2013

Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells

artículo científico publicado en 2014

Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis

artículo científico publicado en 2017

Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma.

artículo científico publicado en 2016

Novel treatment options for refractory Germ Cell Tumours: back to the bench!

artículo científico publicado en 2017

PARP inhibition in castration-resistant prostate cancer

artículo científico publicado en 2016

Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study.

artículo científico publicado en 2016

The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.

artículo científico publicado en 2014

Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis.

artículo científico publicado en 2013

Tumor-to-tumor metastasis: breast cancer metastatic to thymic epithelial tumor

artículo científico publicado en 2013

Lista de obras de Lucia Nappi

Addition of erlotinib to fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab: Two sequential phase I trials

Avelumab and axitinib combination therapy for the treatment of advanced renal cell carcinoma

Building the Case for Adjuvant Chemotherapy After Radical Cystectomy: Commentary on: Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer

Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis.

Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis.

Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma.

Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models

Hsp27 Inhibition with OGX-427 Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy.

Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to antiepidermal growth factor receptor antibody.

Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells

Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis

Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma.

Novel treatment options for refractory Germ Cell Tumours: back to the bench!

PARP inhibition in castration-resistant prostate cancer

Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study.

The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.

Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis.

Tumor-to-tumor metastasis: breast cancer metastatic to thymic epithelial tumor